{
    "Symbol": "MRNA",
    "AssetType": "Common Stock",
    "Name": "Moderna Inc",
    "Description": "Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.",
    "CIK": "1682852",
    "Exchange": "NASDAQ",
    "Currency": "USD",
    "Country": "USA",
    "Sector": "LIFE SCIENCES",
    "Industry": "BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)",
    "Address": "200 TECHNOLOGY SQUARE, CAMBRIDGE, MA, US",
    "FiscalYearEnd": "December",
    "LatestQuarter": "2022-12-31",
    "MarketCapitalization": "57958728000",
    "EBITDA": "9767999000",
    "PERatio": "7.27",
    "PEGRatio": "0",
    "BookValue": "49.67",
    "DividendPerShare": "0",
    "DividendYield": "0",
    "EPS": "20.64",
    "RevenuePerShareTTM": "48.89",
    "ProfitMargin": "0.434",
    "OperatingMarginTTM": "0.489",
    "ReturnOnAssetsTTM": "0.233",
    "ReturnOnEquityTTM": "0.503",
    "RevenueTTM": "19263001000",
    "GrossProfitTTM": "10552000000",
    "DilutedEPSTTM": "20.64",
    "QuarterlyEarningsGrowthYOY": "-0.678",
    "QuarterlyRevenueGrowthYOY": "-0.295",
    "AnalystTargetPrice": "226.64",
    "TrailingPE": "7.27",
    "ForwardPE": "32.47",
    "PriceToSalesRatioTTM": "3.722",
    "PriceToBookRatio": "4.462",
    "EVToRevenue": "3.54",
    "EVToEBITDA": "5.34",
    "Beta": "1.699",
    "52WeekHigh": "217.25",
    "52WeekLow": "115.03",
    "50DayMovingAverage": "167.43",
    "200DayMovingAverage": "157.99",
    "SharesOutstanding": "386340000",
    "DividendDate": "None",
    "ExDividendDate": "None"
}